Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery

Pharmacotherapy

Volumn 23, Issue 6, 2003, Pages 772-787

  Comp, Philip C ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID; ANTICOAGULANT AGENT; ARDEPARIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CERTOPARIN; DALTEPARIN; DANAPAROID; ENOXAPARIN; ENZYME PRECURSOR; FIBRIN; FONDAPARINUX; HEPARIN; HEPARIN DERIVATIVE; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NADROPARIN; OCTANOIC ACID DERIVATIVE; PENTASACCHARIDE; REVIPARIN; SODIUM N [8 (2 HYDROXYBENZOYL)AMINO]CAPRYLATE HEPARIN; THROMBIN; THROMBIN INHIBITOR; TICK ANTICOAGULANT PEPTIDE; TINZAPARIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

BLEEDING; DRUG EFFICACY; DRUG SAFETY; HEMATOMA; HIP FRACTURE; HIP SURGERY; HUMAN; KNEE ARTHROPLASTY; MAJOR SURGERY; ORTHOPEDIC SURGERY; OSTEOPENIA; POSTOPERATIVE COMPLICATION; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; VEIN THROMBOSIS;

FACTOR XA; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; ORTHOPEDIC PROCEDURES; POLYSACCHARIDES; POSTOPERATIVE COMPLICATIONS; THROMBOEMBOLISM;

EID: 0038012642     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.6.772.32190     Document Type: Review

References (152)

1. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119(suppl 1):S132-75.
2. Kaplan KL, Francis CW. Direct thrombin inhibitors. Semin Hematol 2002;39:187-96.
3. Rezaie AR. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins. Thromb Haemost 2003;89:112-21.
4. Bauer KA, Hawkins DW, Peters PC, et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. Cardiovasc Drug Rev 2002;20:37-52.
5. McFarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 1964;202:498-9.
6. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964;145:1310-12.
7. Dahlback B. Blood coagulation. Lancet 2000;355:1627-32.
8. Nemerson Y. Tissue factor and hemostasis. Blood 1988;71:1-8.
9. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991;30:10363-70.
10. Esmon CT. The regulation of natural anticoagulant pathways. Science 1987;235:1348-52.
11. Esmon CT, Schwarz HP. An update on clinical and basic aspects of the protein C anticoagulant pathway. Trends Cardiovasc Med 1995;5:141-8.
12. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995;74:90-3.
13. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973;248:6490-505.
14. Rosenberg RD, Rosenberg JS. Natural anticoagulant mechanisms. J Clin Invest 1984;74:1-6.
15. Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Sims GEC. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976;9:575-83.
16. Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976;69:570-7.
17. Yin ET, Wessler S, Stoll PJ. Identity of plasma-activated factor X inhibitor with antithrombin 3 and heparin cofactor. J Biol Chem 1971;246:3712-19.
18. Danielsson Å, Raub E, Lindahl U, Björk I. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 1986;261:15467-73.
19. Choay J, Lormeau JC, Petitou M, Sinaÿ P, Fareed J. Structural studies on a biologically active hexasaccharide obtained from heparin. Ann N Y Acad Sci 1981;370:644-9.
20. Lindahl U, Backstrom G, Thunberg L. The antithrombin-binding sequence in heparin: identification of an essential 6-O-sulfate group. J Biol Chem 1983;258:9826-30.
21. Walenga JM, Petitou M, Samama M, Fareed J, Choay J. Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activity. Thromb Res 1988;52:553-63.
22. Jin L, Abrahams JP, Skinner R, Petitou M, Pike RN, Carrell RW. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 1997;94:14683-8.
23. Olson ST, Björk I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions: resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992;267:12528-38.
24. Crafoord C, Jorpes E. Heparin as a prophylactic against thrombosis. JAMA 1941;116:2831-5.
25. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 1996;26(suppl 2):24-38.
26. Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992;67:639-43.
27. Denton J, Lane DA, Thunberg L, Slater AM, Lindahl U. Binding of platelet factor 4 to heparin oligosaccharides. Biochem J 1983;209:455-60.
28. Shaughnessy SG, Young E, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 1995;86:1368-73.
29. Boneu B, Caranobe C, Sie P. Pharmacokinetics of heparin and low molecular weight heparin. Baillieres Clin Haematol 1990;3:531-44.
30. Cruickshank MK, Levine MN, Hirsh J, Roberts R, Siguenza M. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991;151:333-7.
31. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119(suppl 1):S64-94.
32. Cade JF, Buchanan MR, Boneu B, et al. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res 1984;35:613-25.
33. Mätzsch T, Bergqvist D, Hedner U, Nilsson B, Østergaard P. Heparin-induced osteoporosis in rats. Thromb Haemost 1986;56:293-4.
34. Warkentin TE. Heparin-induced thrombocytopenia and its treatment. J Thromb Thrombolysis 2000;9(suppl 1):S29-35.
35. Bernardi E, Piccioli A, Oliboni G, Zuin R, Girolami A, Prandoni P. Nomograms for the administration of unfractionated heparin in the initial treatment of acute thromboembolism: an overview. Thromb Haemost 2000;84:22-6.
36. Johnson EA, Kirkwood TBL, Stirling Y, et al. Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection. Thromb Haemost 1976;35:586-91.
37. Messmore HL Jr, Griffin B, Fareed J, Coyne E, Seghatchian J. In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets. Ann NY Acad Sci 1989;556:217-32.
38. Monreal M, Vifias L, Monreal L, Lavin S, Lafoz E, Angles AM. Heparin-related osteoporosis in rats: a comparative study between unfractionated heparin and a low-molecular-weight heparin. Haemostasis 1990;20:204-7.
39. Muir JM, Hirsh J, Weitz JI, Andrew M, Young E, Shaughnessy SG. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood 1997;89:3236-42.
40. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
41. de Raucourt E, Vinsonneau C, Juvin K, Fischer AM, Meyer G. Heparin-induced thrombocytopenia with thrombotic complications during prophylactic treatment with low-molecular-weight heparin. Blood Coagul Fibrinolysis 1996;7:786-8.
42. Barratt SM, Ruff SJ, Edwards RC. Heparin-induced thrombocytopenia presenting after the cessation of low molecular weight heparin prophylaxis with enoxaparin. Med J Aust 2000;172:449.
43. Bick RL, Fareed J. Low molecular weight heparins: differences and similarities in approved preparations in the United States. Clin Appl Thromb Hemost 1999;5(suppl 1):S63-6.
44. Fareed J, Walenga JM, Hoppensteadt D, Racanelli A, Coyne E. Chemical and biological heterogeneity in low molecular weight heparins: implications for clinical use and standardization. Semin Thromb Hemost 1989;15:440-63.
45. Fareed J, Fu K, Yang LH, Hoppensteadt DA. Pharmacokinetics of low molecular weight heparins in animal models. Semin Thromb Hemost 1999;25(suppl 3):51-5.
46. Eriksson BI, Söderberg K, Widlund L, Wandeli B, Tengborn L, Risberg B. A comparative study, of three low-molecular-weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995;73:398-401.
47. Collignon F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995;73:630-40.
48. Turpie AGG. Can we differentiate the low-molecular-weight heparins? Clin Cardiol 2000;23(suppl 1):I-4-7.
49. Ageno W, Turpie AGG. Heparinoids. In: Verstraete M, Fuster V, Topol EJ, eds. Cardiovascular thrombosis: thrombocardiology and thromboneurology. Philadelphia: Lippincott-Raven, 1998:221-34.
50. Fabris F, Luzzatto G, Stefani PM, Girolami B, Cella G, Girolami A. Heparin-induced thrombocytopenia. Haematologica 2000;85:72-81.
51. Sato K, Kawasaki T, Taniuchi Y, Hirayama F, Koshio H, Matsumoto Y. YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time. Eur J Pharmacol 1997;339:141-6.
52. Murayama N, Tanaka M, Kunitada S, et al. Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers. Clin Pharmacol Ther 1999;66:258-64.
53. Vlasuk GP. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemost 1993;70:212-16.
54. Rebello SS, Blank HS, Rote WE, Vlasuk GP, Lucchesi BR. Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration. J Pharmacol Exp Ther 1997;283:91-9.
55. Samama MM, Walenga JM, Kaiser B, Fareed J. Specific factor Xa inhibitors. In: Verstraete M, Fuster V, Topol EJ, eds. Cardiovascular thrombosis: thrombocardiology and thromboneurology. Philadelphia: Lippincott-Raven, 1998:173-88.
56. Dyke CK, Becker RC, Kleiman NS, et al. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation 2002;105:2385-91.
57. Shimbo D, Osende JI, Chen J, Mukherjee JT, Fuster V, Badimon JJ. Antithrombotic effects in humans of escalating doses of DX-9065a, a direct factor Xa inhibitor: comparative study with low molecular weight heparin (enoxaparin) [abstr]. J Am Coll Cardiol 2001;37:A222-3.
58. Choay J, Petitou M, Lormeau JC, Sinaÿ P, Casu B, Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983;116:492-9.
59. van Boeckel CAA, Beetz T, Vos JN, et al. Synthesis of a pentasaccharide corresponding to the antithrombin III binding fragment of heparin. J Carbohydr Chem 1985;4:293-321.
60. Petitou M, Duchaussoy P, Lederman I, et al. Synthesis of heparin fragments: a methyl α-pentaoside with high affinity for antithrombin III. Carbohydr Res 1987;167:67-75.
61. Lormeau JC, Herault JP. The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thromb Haemost 1995;74:1474-7.
62. Lormeau JC, Herault JP, Gaich C, et al. Determination of the anti-factor Xa activity of the synthetic pentasaccharide SR 90107A/ORG 31540 and of two structural analogues. Thromb Res 1997;85:67-75.
63. Herbert JM, Petitou M, Lormeau JC, et al. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 1997;15:1-26.
64. Turpie AGG, Gallus AS, Hoek JA, for the Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001;344:619-25.
65. Paolucci F, Clavies MC, Donat F, Necciari J. Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin Pharmacokinet 2002;41(suppl 2):11-18.
66. Amiral J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997;8:114-17.
67. Ahmad S, Jeske WP, Walenga JM, et al. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost 1999;5:259-66.
68. Elalamy I, LeCrubier C, Potevin F, et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia [letter]. Thromb Haemost 1995;74:1384-5.
69. Boneu B, Necciari J, Cariou R, et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. Thromb Haemost 1995;74:1468-73.
70. Donat F, Duret JP, Santoni A, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002;41(suppl 2):1-9.
71. Wessler S, Yin ET. On the antithrombotic action of heparin. Thromb Diath Haemorrh 1974;32:71-8.
72. Verstraete M, Zoldhelyi P, Willerson JT. Specific thrombin inhibitors. In: Verstraete M, Fuster V, Topol EJ, eds. Cardiovascular thrombosis: thrombocardiology and thromboneurology. Philadelphia: Lippincott-Raven, 1998:141-72.
73. Suttie JW. The biochemical basis of warfarin therapy. In: Wessler S, Becker CG, Nemerson Y, eds. The new dimensions of warfarin prophylaxis. New York: Plenum Press, 1987:3-16.
74. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002;359:1721-6.
75. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002;359:1715-20.
76. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-10.
77. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345:1298-304.
78. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370-6.
79. Hamulyak K, Lensing AWA, van der Meer J, et al. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Thromb Haemost 1995;74:1428-31.
80. RD Heparin Arthroplasty Group. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg Am 1994;76:1174-85.
81. Francis CW, Pellegrini VD Jr, Totterman S, et al. Prevention of deep-vein thrombosis after total hip arthroplasty: comparison of warfarin and dalteparin. J Bone Joint Surg Am 1997;79:1365-72.
82. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. Arch Intern Med 2000;160:2199-207.
83. Francis CW, Pellegrini VD Jr, Marder VJ, et al. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA 1992;267:2911-15.
84. Paiement G, Wessinger SJ, Waltman AC, Harris WH. Low-dose warfarin versus external pneumatic compression for prophylaxis against venous thromboembolism following total hip replacement. J Arthroplasty 1987;2:23-6.
85. Bailey JP, Kruger MP, Solano FX, Zajko AB, Rubash HE. Prospective randomized trial of sequential compression devices vs low-dose warfarin for deep venous thrombosis prophylaxis in total hip arthroplasty. J Arthroplasty 1991;6(suppl):S29-35.
86. Lotke PA, Palevsky H, Keenan AM, et al. Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Clin Orthop 1996;Mar(326):251-8.
87. Kaempffe FA, Lifeso RM, Meinking C. Intermittent pneumatic compression versus Coumadin: prevention of deep vein thrombosis in lower-extremity total joint arthroplasty. Clin Orthop 1991;Aug(269):89-97.
88. Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988;60:407-10.
89. Colwell CW Jr, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement: a clinical trial comparing efficacy and safety. J Bone Joint Surg Am 1994;76:3-14.
90. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991;114:545-51.
91. Planès A, Vochelle N, Fagola M, Feret J, Bellaud M. Prevention of deep vein thrombosis after total hip replacement: the effect of low-molecular-weight heparin with spinal and general anaesthesia. J Bone Joint Surg Br 1991;73:418-22.
92. Planès A, Vochelle N, Fagola M, Bellaud M. Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery: reviparin study group. Blood Coagul Fibrinolysis 1998;9:499-505.
93. Leyvraz PF, Bachmann F, Hoek J, et al. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ 1991;303:543-8.
94. The German Hip Arthroplasty Trial (GHAT) Group. Prevention of deep vein thrombosis with low-molecular-weight heparin in patients undergoing total hip replacement: a randomized trial. Arch Orthop Trauma Surg 1992;111:110-20.
95. Dechavanne M, Ville D, Berruyer M, et al. Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. Haemostasis 1989;19:5-12.
96. Eriksson BI, Kälebo P, Anthymyr BA, Wadenvik H, Tengborn L, Risberg B. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement: comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am 1991;73:484-93.
97. Barre J, Pfister G, Potron G, et al. Comparison of the efficacy and tolerance of Kabi 2165 and standard heparin in the prevention of deep venous thrombosis in total hip prosthesis [in French]. J Mal Vasc 1987;12(suppl B):90-5.
98. Eriksson BI, Ekman S, Kälebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996;347:635-9.
99. Eriksson BI, Ekman S, Lindbratt S, et al. Prevention of thromboembolism with use of recombinant hirudin: results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 1997;79:326-33.
100. Leyvraz PF, Richard J, Bachmann F, et al. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deepvein thrombosis after total hip replacement. N Engl J Med 1983;309:954-8.
101. Gallus AS, Cade JF, Mills KW, Murphy W. Apparent lack of synergism between heparin and dihydroergotamine in prevention of deep vein thrombosis after elective hip replacement: a randomised double-blind trial reported in conjunction with an overview of previous results. Thromb Haemost 1992;68:238-44.
102. Turpie AGG, Levine MN, Hirsh J, et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986;315:925-9.
103. Spiro TE, Johnson GJ, Christie MJ, et al. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Ann Intern Med 1994;121:81-9.
104. Eriksson BI, Wille-Jørgensen P, Kälebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329-35.
105. Kalodiki EP, Hoppensteadt DA, Nicolaides AN, et al. Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement: a randomised controlled trial. Int Angiol 1996;15:162-8.
106. Danish Enoxaparin Study Group. Low-molecular-weight heparin (enoxaparin) vs dextran 70: the prevention of postoperative deep vein thrombosis after total hip replacement. Arch Intern Med 1991;151:1621-4.
107. Bergqvist D, Benoni G, Björgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335:696-700.
108. Planès A, Samama MM, Lensing AWA, et al. Prevention of deep vein thrombosis after hip replacement: comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin. Thromb Haemost 1999;81:22-5.
109. Lassen MR, Borris LC, Christiansen HM, et al. Prevention of thromboembolism in 190 hip arthroplasties: comparison of LMW heparin and placebo. Acta Orthop Scand 1991;62:33-8.
110. Lassen MR, Borris LC, Jensen HP, Poulsen KA, Ejstrud P, Andersen BS. Dose relation in the prevention of proximal vein thrombosis with a low molecular weight heparin (tinzaparin) in elective hip arthroplasty. Clin Appl Thromb Hemost 2000;6:53-7.
111. Fitzgerald RH Jr, Spiro TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty: a randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 2001;83:900-6.
112. Leelerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty: a randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996;124:619-26.
113. Heit JA, Berkowitz SD, Bona R, et al. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Thromb Haemost 1997;77:32-8.
114. Francis CW, Pellegrini VD Jr, Leibert KM, et al. Comparison of two warfarin regimens in the prevention of venous thrombosis following total knee replacement. Thromb Haemost 1996;75:706-11.
115. Colwell CW Jr, Spiro TE, Trowbridge AA, et al. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Clin Orthop 1995;Dec(321):19-27.
116. Faunø P, Suomalainen O, Rehnberg V, et al. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty: a comparison between unfractionated and low-molecular-weight heparin. J Bone Joint Surg Am 1994;76:1814-18.
117. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of deep vein thrombosis after major knee surgery: a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992;67:417-23.
118. Blanchard J, Meuwly JY, Leyvraz PF, et al. Prevention of deep-vein thrombosis after total knee replacement: randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. J Bone Joint Surg Br 1999;81:654-9.
119. Levine MN, Gent M, Hirsh J, et al. Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism: a randomized trial in patients undergoing knee surgery. Arch Intern Med 1996;156:851-6.
120. Gerhart TN, Yett HS, Robertson LK, Lee MA, Smith M, Salzman EW. Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip: a prospective, randomized trial. J Bone Joint Surg Am 1991;73:494-502.
121. Powers PJ, Gent M, Jay RM, et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med 1989;149:771-4.
122. Monreal M, Lafoz E, Navarro A, et al. A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture. J Trauma 1989;29:873-5.
123. Moskovitz PA, Ellenberg SS, Feffer HL, et al. Low-dose heparin for prevention of venous thromboembolism in total hip arthroplasty and surgical repair of hip fractures. J Bone Joint Surg Am 1978;60:1065-70.
124. Thromboprophylaxis in Fracture Surgery: Danaparoid, Enoxaparin, Dalteparin Study Group. Thromboprophylaxis in hip fracture surgery: a pilot study comparing danaparoid, enoxaparin and dalteparin. Haemostasis 1999;29:310-17.
125. Barsotti J, Gruel Y, Rosset P, et al. Comparative double-blind study of two dosage regimens of low-molecular weight heparin in elderly patients with a fracture of the neck of the femur. J Orthop Trauma 1990;4:371-5.
126. Bergqvist D, Kettunen K, Fredin H, et al. Thromboprophylaxis in patients with hip fractures: a prospective, randomized, comparative study between Org 10172 and dextran 70. Surgery 1991;109:617-22.
127. Gent M, Hirsh J, Ginsberg JS, et al. Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Circulation 1996;93:80-4.
128. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a metaanalysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-40.
129. Lassen MR, Backs S, Borris LC, Kaltoft-Sørenson M, CoffGanes H, Jeppesen E. Deep-vein thrombosis prophylaxis in orthopedic surgery: hip surgery. Semin Thromb Hemost 1999;25(suppl 3):79-82.
130. Graafsma YP, Prins MH, Lensing AWA, de Haan RJ, Huisman MV, Büller HR. Bleeding classification in clinical trials: observer variability and clinical relevance. Thromb Haemost 1997;78:1189-92.
131. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988;318:1162-73.
132. Harris WH, Salzman EW, Athanasoulis C, Waltman AC, Baum S, DeSanctis RW. Comparison of warfarin, low-molecular-weight dextran, aspirin, and subcutaneous heparin in prevention of venous thromboembolism following total hip replacement. J Bone Joint Surg Am 1974;56:1552-62.
133. Colwell CW Jr, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999;81:932-40.
134. Stern SH, Wixson RL, O'Connor D. Evaluation of the safety and efficacy of enoxaparin and warfarin for prevention of deep vein thrombosis after total knee arthroplasty. J Arthroplasty 2000;15:153-8.
135. Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. J Bone Joint Surg Am 2001;83:336-45.
136. Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996;348:224-8.
137. McNally MA, Cooke EA, Harding ML, Mollan RA. Attitudes to, and utilization of, low molecular weight heparins in joint replacement surgery. J R Coll Surg Edinb 1997;42:407-9.
138. Borris LC, Lassen MR. A comparative review of the adverse effect profiles of heparins and heparinoids. Drug Saf 1995;12:26-31.
139. Lumpkin MM. FDA public health advisory. Anesthesiology 1998;88:A27-8.
140. Turpie AG. Use of selective factor Xa inhibitors in special populations. Am J Orthop 2002;31(suppl 11):11-15.
141. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001;161:2215-21.
142. Eriksson BI, Arfwidsson AC, Frison L, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. Thromb Haemost 2002;87:231-7.
143. Eriksson BI, Bergqvist D, Kälebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002;360:1441-7.
144. Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip replacement. Thromb Haemost 2003;89:288-96.
145. Colwell CW, Berkowitz SD, Davidson BL, et al. Randomized, double-blind, comparison of ximelagatran, an oral direct thrombin inhibitor, and enoxaparin to prevent venous thromboembolism (VTE) after total hip arthroplasty (THA) [abstr]. Blood 2001;98:706a.
146. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thrombo-embolism after total knee arthroplasty: a randomized, double-blind trial. Ann Intern Med 2002;137:648-55.
147. Francis CW, Berkowitz SD, Comp PC, et al. Randomized, double-blind, comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR) [abstr]. Blood 2002;100:82a.
148. Eriksson BI, Agnelli G, Cohen AT, et al. The oral direct thrombin inhibitor ximelagatran, and its subcutaneous (sc) form melagatran, compared with enoxaparin for prophylaxis of venous thromboembolism (VTE) in total hip or total knee replacement (THR or TKR): the EXPRESS study [abstr]. Blood 2002;100:82a.
149. Baughman RA, Kapoor SC, Agarwal RJ, Kisicki J, Catella-Lawson F, FitzGerald GA. Oral delivery of anticoagulant doses of heparin: a randomized, double-blind, controlled study in humans. Circulation 2001;98:1610-15.
150. Gonze MD, Salartash K, Sternbergh WC III, Baughman RA, Leone-Bay A, Money SR. Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Circulation 2000;101:2658-61.
151. Salartash K, Lepore M, Gonze MD, et al. Treatment of experimentally induced caval thrombosis with oral low molecular weight heparin and delivery agent in a porcine model of deep venous thrombosis. Ann Surg 2000;231:789-94.
152. Hull RD, Kakkar AK, Marder VJ, Pineo GF, Goldberg MM, Raskob GE. Oral SNAC-heparin vs enoxaparin for preventing venous thromboembolism following total hip replacement. Presented at the 44th annual meeting of the American Hematology Society, Philadelphia, December 6-10, 2002.